Equine Infectious Anemia Virus

Overview and Taxonomy of Equine Infectious Anemia Virus

Equine Infectious Anemia Virus (EIAV) constitutes the etiological agent of one of the most historically significant and economically consequential viral diseases affecting the global equid population. As a member of the Retroviridae family, EIAV is classified within the genus Lentivirus, a group of non-oncogenic, exogenously acquired retroviruses characterized by protracted incubation periods, persistent infection, and progressive pathological outcomes [3, 6]. This taxonomic positioning places EIAV in close phylogenetic proximity to the human immunodeficiency viruses (HIV-1 and HIV-2), as well as other lentiviruses of veterinary importance, including the feline immunodeficiency virus (FIV) and the simian immunodeficiency viruses (SIV) [3]. The World Organisation for Animal Health (WOAH) designates EIA as a notifiable disease, underscoring its critical importance to international equine trade and biosecurity, given that infected equids become lifelong carriers and reservoirs for transmission [9, 11]. The disease, colloquially known as "swamp fever," was first recognized in France in 1843, with the viral etiology established much later. The virus has since been documented across all continents where equids are maintained, revealing a complex global distribution pattern that is modulated by ecological, climatic, and anthropogenic factors [1, 15].

Taxonomic Classification and Phylogenetic Relationships

EIAV is unequivocally classified as a member of the Lentivirus genus within the subfamily Orthoretrovirinae, family Retroviridae [11, 13]. It is widely recognized as the simplest and most genetically compact of all known lentiviruses, making it an invaluable model for understanding fundamental aspects of lentiviral biology, replication, and the interplay with host restriction factors [3, 6]. The virus possesses a diploid, single-stranded, positive-sense RNA genome of approximately 8.2 kilobases, which is reverse-transcribed into a double-stranded DNA provirus upon entry into the host cell [20, 22]. Compared to HIV-1, the EIAV genome encodes only three major structural genes, gag, pol, and env, along with three accessory/regulatory genes: tat, rev, and the unique S2 gene [6, 16]. Critically, recent investigations have identified a novel viral protein designated Grev, a second post-transcriptional transactivator encoded by a distinct single-spliced transcript containing two exons, which mediates the nuclear export of mat mRNA via the CRM1 pathway, suggesting that the post-transcriptional regulatory architecture of EIAV is more complex than previously appreciated [8]. This discovery of Grev, alongside the canonical Rev protein, which itself is encoded by a four-exon, multiple-spliced transcript, highlights the intricate and sophisticated nature of EIAV gene regulation despite its genomic economy [8].

Phylogenetic analyses based on the gag gene, the LTR (long terminal repeat), and whole-genome sequences have consistently revealed that EIAV isolates form a monophyletic group, yet exhibit substantial genetic diversity that partitions into distinct global lineages [9, 15]. A landmark phylogeographic reconstruction utilizing Bayesian phylodynamic approaches posited that modern EIAV circulation likely originated from Europe, with Hungary identified as the most probable ancestral geographic source (root state posterior probability = 0.21), and Europe itself identified as the continent harboring the highest degree of phylogenetic diversity [15]. This historical dispersal pattern was characterized predominantly by long-distance transcontinental movements, likely coinciding with the transport of equids by humans over centuries [15]. Consequently, American and Mongolian isolates are phylogenetically more closely related to European lineages than to other Asian strains, a pattern consistent with the reintroduction of Equidae into the Americas by European colonizers [16, 23]. For instance, comparative genomic analysis of four geographically distinct North American isolates (from Pennsylvania, Tennessee, North Carolina, and Florida) revealed that while they comprise a single monophyletic group associated with an Irish isolate, nucleotide sequence identity between them was surprisingly limited, ranging from only 80.1% to 84.6% [16]. These values are not substantially higher than the sequence identity between a Pennsylvania isolate and Asian strains (78.0–75.4%), indicating that significant genetic divergence has occurred even within continental populations [16].

A groundbreaking study from an endemic region of Brazil (Pantanal) provided the first complete genomic sequences of EIAV RNA from naturally infected horses, revealing that Brazilian field strains are highly divergent, sharing only 88.6% nucleotide identity with each other and a mere 75.8 to 77.3% identity with principal reference strains such as EIAV Liaoning, Wyoming, Ireland, and Italy [14]. Phylogenetic analysis placed these Brazilian sequences into a separate, distinct monophyletic group, suggesting long-standing, independent evolution in the South American equid populations [11, 14]. Similarly, a full-genome sequence obtained from a horse in the Western Balkan region of Serbia (Vojvodina) formed a new, distinct cluster, further illustrating that EIAV genetic diversity is expanding and that circulating strains in under-sampled regions represent novel clades [9]. The env gene, particularly the region encoding the surface glycoprotein gp90 and the transmembrane gp45, along with the LTR, are the most variable genomic regions, driving antigenic variation and immune evasion [14, 16]. In contrast, the gag and pol genes are relatively more conserved, though notable variations exist even within the p26 capsid protein, a primary target for serological diagnosis, where amino acid substitutions on surface-exposed epitopes have been documented in Brazilian strains [14].

Virion Morphology and Genomic Architecture

The mature EIAV virion is spherical to pleomorphic, measuring approximately 90 to 120 nm in diameter [22]. It is enveloped by a lipid bilayer derived from the host cell plasma membrane, into which are embedded trimeric spikes of the envelope glycoprotein complex. This complex consists of two non-covalently associated subunits: the surface unit (SU), gp90 (approximately 90 kDa), which mediates receptor attachment, and the transmembrane unit (TM), gp45 (approximately 45 kDa), which anchors the complex and facilitates membrane fusion [2, 4, 12]. The EIAV Env harbors the longest cytoplasmic tail (CT) of any lentivirus, a feature that has been shown to intricately regulate Env trafficking, precursor cleavage, and plasma membrane localization, thereby modulating virion production and, critically, attenuation of virulence [12]. Truncation of this CT, such as that observed in the live attenuated vaccine strain, significantly increases Env cleavage and plasma membrane localization, leading to enhanced particle production [12].

Beneath the envelope lies the viral matrix, composed of the p15 (MA) protein, surrounding a conical core (nucleocapsid) made from p26 (CA) [19, 22]. Within the core reside two identical copies of the single-stranded RNA genome, tightly complexed with the nucleocapsid protein NCp11, which possesses remarkable thermostable properties and is critical for viral RNA packaging and reverse transcription [19]. The genome itself is flanked at both ends by the LTRs, which contain essential cis-acting elements for transcription, including the U3 region (harboring the enhancer and promoter with binding sites for host transcription factors), the R region (containing the TAR element and transcription start site), and the U5 region [18, 25]. The LTR is a key determinant of viral replication kinetics and cell tropism, and quasispecies variation, particularly within the U3 enhancer region and the negative regulatory element (NRE), is intimately linked to the attenuation of pathogenicity during the development of the Chinese live attenuated vaccine [18].

Host Range, Cellular Tropism, and Integration

The natural host range of EIAV is restricted to members of the family Equidae, including horses (Equus ferus caballus), donkeys (Equus asinus), and mules, with no evidence of natural infection in other livestock, wildlife, or humans [11, 22]. Within the infected host, the primary cellular targets are cells of the monocyte/macrophage lineage [24, 26]. Notably, the attenuated vaccine strain EIAVDLV121 primarily infects monocytes and macrophages, whereas its virulent parental strain (EIAVLN40) also exhibits expanded tropism, capable of infecting alveolar epithelial cells and vascular endothelial cells, which likely contributes to the severe pathological outcomes associated with virulent infection [24]. The species-specificity of EIAV is partially dictated by the requirement for equine lentivirus receptor 1 (ELR1), a member of the tumor necrosis factor receptor (TNFR) superfamily, and the equine cyclin T1 (eCT1) cofactor, which are essential for viral entry and Tat-mediated transactivation of the LTR, respectively [26]. Transgenic mice constructed to express both equine ELR1 and eCT1 have been shown to be susceptible to EIAV infection and replication, with viral detection in plasma, spleen, and lymph nodes, establishing a small animal model for studying lentiviral pathogenesis [26]. A defining feature of lentiviral infection is the integration of the proviral DNA into the host cell genome. EIAV integration exhibits a distinct profile in its natural equine host, showing a preference for integration within genes and AT-rich regions, particularly within long interspersed elements (LINEs) and DNA transposons, while disfavoring transcription start sites [25]. This genomic integration site selection is critical for establishing viral latency and persistent infection, imposing lifelong carriage and complicating eradication efforts [9, 25].

Antigenic Composition and Immunological Targets

The EIAV proteome presents several key immunogenic proteins that serve as targets for both antibody-based and cell-mediated immune responses, as well as for diagnostic detection. The most widely used serological target is the capsid protein p26, which is highly conserved and forms the basis of the prescribed WOAH gold standard diagnostic test, the agar gel immunodiffusion (AGID) test [4, 5, 7]. However, the envelope glycoproteins, gp90 (SU) and gp45 (TM), are the primary targets of the neutralizing antibody response and are also critical for eliciting cytotoxic T lymphocyte (CTL) responses [4, 10, 28]. The gp90 protein is heavily glycosylated and contains highly variable regions that are subject to immune selection pressure and antigenic drift, allowing for CTL escape, which is a major mechanism of viral persistence [28]. The more conserved features of gp90 and the fusion peptide of gp45 are exploited for more sensitive serological detection methods, such as peptide-based ELISAs, which can identify infections missed by the p26-based AGID test [4, 10, 21]. In addition to structural proteins, the Tat protein is essential for viral transcription, and the Rev and Grev proteins regulate nucleocytoplasmic transport of viral mRNAs [3, 8]. The S2 accessory protein plays roles in viral pathogenesis and counteracting host restriction factors [6]. Understanding the specific interactions between these viral proteins and host cellular partners, including restriction factors like equine MX2, which potently restricts EIAV through a GTPase-dependent mechanism, and the AP-2 and AIP1/Alix endocytic proteins involved in the unique YPDL L-domain-mediated budding process, provides foundational knowledge for understanding lentiviral replication and for designing future therapeutic interventions [3, 6, 17, 27].

Molecular Pathogenesis of EIAV: Viral Replication and Immune Evasion

Equine Infectious Anemia Virus (EIAV), the etiological agent of equine infectious anemia (EIA), is the archetypal and most genomically streamlined member of the lentivirus genus within the Retroviridae family [3, 6]. Despite its relative genetic simplicity, EIAV orchestrates a remarkably complex and dynamic interplay with the equine host, characterized by a life-long persistent infection punctuated by recurrent febrile episodes and a sophisticated arsenal of immune evasion strategies. The molecular pathogenesis of EIAV is fundamentally a narrative of viral replication, host restriction, and counter-restriction, where the virus’s minimal genome is leveraged to hijack cellular machinery while simultaneously subverting both intrinsic and adaptive immune defenses. Understanding these molecular mechanisms is not only critical for controlling EIA, a disease of significant economic and regulatory concern to the global equine industry as recognized by the World Organisation for Animal Health (WOAH), but also provides a unique comparative model for understanding the pathogenesis of more complex lentiviruses like HIV-1 [6, 20, 29].

The Viral Life Cycle: A Minimalist Blueprint for Replication

The EIAV replication cycle, from receptor binding to budding, is a masterclass in efficiency, utilizing a limited set of viral proteins to commandeer host cell functions. The initial step of entry is mediated by the viral envelope glycoprotein (Env), a trimeric complex composed of a surface unit (SU, gp90) and a transmembrane unit (TM, gp45) [12, 33]. Gp90 is responsible for binding to the equine lentivirus receptor 1 (ELR1), a member of the tumor necrosis factor receptor (TNFR) superfamily, which is expressed on the surface of equine monocytes and macrophages, the primary target cells for EIAV [26]. This interaction is a critical determinant of host tropism. Following receptor binding, gp45 facilitates the fusion of the viral and cellular membranes, a process that is exquisitely regulated by the unusually long cytoplasmic tail (CT) of the Env protein. Research has demonstrated that this CT acts as a molecular rheostat, modulating Env processing and trafficking. Specifically, the CT inhibits the cleavage of the Env precursor (gp140) into its functional SU and TM subunits and promotes rapid endocytosis of Env from the plasma membrane, thereby limiting its incorporation into budding virions [12]. This regulatory mechanism is hypothesized to balance virion production, preventing excessive cytopathology and facilitating persistent infection. Notably, truncations of this CT, observed in the live-attenuated EIAV vaccine strain, result in enhanced Env cleavage, increased plasma membrane localization, and a significant boost in virion production, linking this molecular feature directly to attenuation [12].

Once inside the cell, the viral RNA genome is reverse transcribed into double-stranded DNA by the viral reverse transcriptase (RT). This process is facilitated by the nucleocapsid protein (NCp11), a small, basic, zinc-finger protein that exhibits remarkable thermostability, retaining its nucleic acid chaperone activity even after prolonged incubation at 100°C [19]. NCp11 binds to the viral packaging signal and promotes the efficient synthesis of the first-strand cDNA, a critical step for the establishment of the provirus [19]. The resulting proviral DNA is then transported to the nucleus and integrated into the host cell genome by the viral integrase. EIAV integration is not random; studies mapping integration sites in equine fetal dermal cells have revealed a distinct preference for transcription units and AT-rich regions, while actively avoiding transcription start sites [25]. Furthermore, EIAV shows a unique predilection for integrating into long interspersed nuclear elements (LINEs) and DNA transposons within the horse genome, a pattern distinct from HIV-1’s preference for short interspersed elements (SINEs) [25]. This specific integration landscape likely influences viral transcription, latency, and the long-term persistence of the virus in its natural host.

Post-Transcriptional Regulation: The Rev and Grev Axis

A defining feature of lentiviral replication is the requirement for a post-transcriptional transactivator to export unspliced and singly-spliced viral mRNAs from the nucleus to the cytoplasm. EIAV, despite its genomic simplicity, encodes not one, but two such proteins: the canonical Rev and a recently discovered second transactivator, Grev [8]. Rev, common to all lentiviruses, binds to a rev-responsive element (RRE) within the env-coding region, facilitating the nuclear export of gag/pol and env mRNAs via the CRM1 pathway, which is essential for the expression of structural proteins [8]. The discovery of Grev, a fusion protein comprising the first 18 amino acids of Gag and the last 82 amino acids of Rev, reveals an unexpected layer of regulatory complexity. Grev is encoded by a novel, singly-spliced transcript and, like Rev, localizes to the nucleus and mediates the expression of the Mat protein, a recently identified viral protein of unknown function [8]. However, Grev cannot substitute for Rev in mediating Gag/Pol expression. Instead, Grev specifically binds to a distinct rev-responsive element (RRE-2) located within the first exon of mat mRNAs, exporting them via the same CRM1 pathway but without the requirement for multimerization that is critical for Rev function [8]. This dual-transactivator system suggests that EIAV has evolved a sophisticated, bifurcated post-transcriptional regulatory network, allowing for the independent control of structural protein expression (via Rev) and accessory protein expression (via Grev), fine-tuning the viral replication program.

Intrinsic Immunity and Viral Countermeasures: The Battle with Restriction Factors

The equine host is equipped with a formidable arsenal of intrinsic antiviral proteins, known as restriction factors, which target various stages of the retroviral life cycle. EIAV, in turn, has evolved elegant countermeasures to neutralize these defenses, a molecular arms race that is central to its pathogenesis. One of the most potent equine restriction factors is equine myxovirus resistance protein 2 (eMX2). While its human ortholog, hMXB, restricts HIV-1 but not EIAV, eMX2 potently inhibits EIAV replication in vitro [17]. The mechanism of eMX2 restriction appears to be distinct from that of hMXB. For hMXB, the N-terminal 25 amino acids are critical for antiviral activity, whereas deletion of this region in eMX2 does not diminish its restriction of EIAV. Conversely, mutations in the GTP-binding domain (K127A) and GTP-hydrolysis domain (T147A) of eMX2, which are analogous to loss-of-function mutations in hMXB, completely abrogate its antiviral activity [17]. This indicates that eMX2 inhibits EIAV through a GTPase-dependent mechanism that is mechanistically different from hMXB, likely targeting a post-entry step such as nuclear import or integration.

Beyond MX2, the EIAV p9 protein, which contains the unique YPDL late (L) domain, plays a crucial role in both viral budding and counteracting host defenses. The YPDL motif is a master key that engages multiple cellular endocytic pathways to facilitate the final step of virion release. It interacts with the μ2 subunit of the AP-2 adaptor complex (involved in early endocytosis) and with AIP1/Alix (involved in late endosome formation), demonstrating a comprehensive hijacking of the vesicle trafficking machinery [27]. This dual engagement is essential for efficient EIAV budding, and disruption of either pathway suppresses virion production [27]. Furthermore, the interplay between EIAV and other restriction factors, such as tetherin and the SERINC family, though less well-characterized in the equine system, is an active area of research that promises to reveal further layers of this host-virus conflict [6]. The successful development of the only widely used lentiviral vaccine, the Chinese attenuated EIAV vaccine, is a testament to the fact that these restriction factor barriers can be overcome through viral adaptation, providing a unique model for understanding how attenuation alters the balance between viral replication and host restriction [6, 20, 24].

Immune Evasion: Antigenic Variation and Cellular Sabotage

The hallmark of EIAV pathogenesis is its ability to establish a persistent infection despite a robust host immune response. This is achieved through a multi-pronged strategy of immune evasion, centered on extreme genetic variability and the direct modulation of immune cell function. The primary driver of immune escape is the rapid and continuous mutation of the viral envelope glycoproteins, particularly gp90. This antigenic variation allows the virus to generate a swarm of quasispecies that constantly outpaces the neutralizing antibody response [14, 16, 31]. Each new febrile episode is associated with the emergence of a new antigenic variant of gp90 that is not neutralized by pre-existing antibodies, leading to a new wave of viremia [28]. This relentless cycle of mutation and selection is a key reason why natural immunity is unable to clear the infection.

EIAV also employs sophisticated strategies to subvert the cellular immune response, particularly cytotoxic T lymphocytes (CTLs). While CTLs are critical for controlling viral load, their effectiveness is limited by viral escape. Studies have shown that high-avidity CTLs targeting non-variable epitopes, such as those within the Rev protein, are associated with low viral loads and mild disease (non-progressors) [28]. In contrast, CTL responses directed against variable epitopes in gp90 are rapidly evaded through mutation, leading to viral escape and disease progression [28]. This underscores that the specificity of the CTL response, rather than its magnitude alone, is a critical determinant of disease outcome.

Furthermore, the virus directly manipulates the host’s innate immune signaling. The attenuated EIAV vaccine strain (EIAVFDDV13) has been shown to induce a strong resistance to subsequent infection by a virulent strain in equine monocyte-derived macrophages (eMDMs) [34]. This resistance is mediated, at least in part, through the upregulation of Toll-like receptor 3 (TLR3), interferon-β (IFNβ), and a soluble form of the EIAV receptor (sELR1), which can act as a decoy to block viral entry [34]. The virulent strain, in contrast, fails to induce this protective state, suggesting that pathogenic EIAV strains have evolved mechanisms to suppress or avoid triggering these innate antiviral pathways. This differential induction of a TLR3-mediated antiviral state is a critical molecular distinction between a protective, attenuated virus and a pathogenic one, highlighting a key mechanism of immune evasion by virulent strains. The ability of EIAV to establish “occult” infections, where horses harbor proviral DNA for extended periods without seroconversion, represents the ultimate form of immune evasion, allowing the virus to persist undetected by standard serological surveillance methods [32]. This phenomenon, documented in naturally infected horses, underscores the profound adaptability of EIAV and presents a significant challenge for eradication efforts [30, 32].

Global Epidemiology of Equine Infectious Anemia: Prevalence, Risk Factors, and Vector Dynamics

Equine Infectious Anemia (EIA), caused by the equine infectious anemia virus (EIAV), represents a persistent and globally significant threat to equine health, with profound economic implications for the equine industry worldwide. The World Organisation for Animal Health (WOAH) classifies EIA as a notifiable disease, underscoring its importance in international trade and equine movement. Despite decades of surveillance and control efforts, the global epidemiological landscape of EIAV remains highly heterogeneous, characterized by stark contrasts between regions of low, stable prevalence and areas where the virus circulates at alarming rates. Understanding the intricate interplay between prevalence patterns, risk factors, and vector dynamics is paramount for designing effective, region-specific control strategies. The most comprehensive global assessment of EIAV prevalence in the 21st century, a 24-year retrospective review of literature published between 2000 and 2024, analyzed 105 articles across 42 countries and revealed an estimated global seroprevalence that varies dramatically by geographic region, diagnostic methodology, and the population studied [1]. This analysis firmly establishes that EIAV is not a monolithic entity but a pathogen whose epidemiology is shaped by a complex matrix of ecological, climatic, management, and viral genetic factors.

Global Prevalence and Regional Variations

The distribution of EIAV is profoundly uneven, with the highest documented seroprevalence concentrated in the Americas. The global review identifies Mexico as having the highest estimated prevalence at 27.14% (95% CI, 25.11–29.17), followed by Guatemala in Central America at 15.9% (95% CI, 9.66–22.14) [1]. These figures represent a stark contrast to the situation in the United States, where prevalence remains low and stable, yet risk is not uniformly distributed. Within the USA, elevated prevalence is consistently reported in the Southern states, particularly those sharing an extensive border with Mexico, creating a high-risk corridor for cross-border transmission [1]. This north-south gradient in North America mirrors patterns observed in South America, where Brazil and Argentina exhibit significant intra-country variation. In Brazil, the highest prevalence is heavily concentrated in the Northeast, Central-West, and North regions. An analysis of 111,826 reported EIA cases in Brazil over an 18-year period (2006–2023) demonstrated that the Northeast region alone accounted for 39.75% of all cases, with the state of Ceará exhibiting an incidence risk of 8287.84 per 100,000 horses [41]. The Pantanal region, an endemic stronghold, has been a particular focus of research, with seroprevalence rates approaching 40% in feral equid populations [36, 38]. Phylogenetic analysis of Brazilian EIAV strains from the Pantanal and Northeast regions reveals that these isolates form a distinct monophyletic group, separate from North American, European, and Asian lineages, suggesting a long history of independent viral evolution in this ecologically unique environment [11, 14, 39]. This genetic divergence has practical implications for diagnostics, as amino acid changes identified in the p26 protein, a common diagnostic target, may affect test performance in these endemic regions [14].

In contrast to the high burdens in the Americas, the Middle East presents a markedly different picture. Surveillance studies from Saudi Arabia, representing the first EIAV assessment in the Gulf region, found no serological or molecular evidence of the virus in 361 horses and 19 donkeys tested between 2014 and 2016 [40]. Similarly, EIAV appears to have a low presence in other parts of the Middle East, though the scarcity of comprehensive studies complicates definitive conclusions [1]. The situation in Europe is equally variable. Hungary has been identified by phylogeographic reconstruction as the most likely country of origin for the current global circulation of EIAV (root state posterior probability = 0.21), and historical patterns demonstrate that European lineages have served as a major source for long-distance viral spread across continents [15]. The first report of EIAV in Serbia, in the Western Balkans, documented a low prevalence of 1.6% in 316 tested horses, and intriguingly, the full-genome sequence from this isolate formed a new, distinct phylogenetic cluster [9]. This highlights that even in regions with low overall prevalence, pockets of genetically unique viral strains may be circulating undetected. The presence of EIAV in Mongolia, with 11 of 776 horse sera testing positive by AGID, further illustrates its persistence in geographically isolated equid populations, with Mongolian strains clustering with European genotypes rather than those from neighboring China [23].

Data gaps remain a critical barrier to understanding the full global picture. Africa and Oceania are characterized by a scarcity of epidemiological studies, making it impossible to accurately estimate EIAV prevalence across these large and ecologically diverse continents [1]. The first molecular record of EIAV in Iraq, from central provinces, reported a 16.66% infection rate in horses (but 0% in donkeys) using PCR targeting the gag gene, signaling that the virus is likely underreported in many parts of the Middle East and Asia [37]. In China, the development and widespread deployment of an attenuated live vaccine in the 1970s has been remarkably effective in controlling clinical disease, yet the virus persists in the population, and molecular detection methods must account for the high genetic diversity of Asian strains, which often have low homology with the European and American strains targeted by standard WOAH-recommended qPCR assays [20, 35].

Risk Factors for EIAV Infection

The risk of EIAV infection is not randomly distributed; it is strongly modulated by host-level, management-level, and environmental factors. At the host level, age has emerged as a significant risk factor in several studies. In the Metropolitan Zone of the Valley of Mexico, a high-risk group of horses under four years of age was identified using a highly sensitive synthetic gp90 peptide ELISA, suggesting that younger animals may be more susceptible to infection or that they represent a population with recent exposure [4]. This finding challenges the traditional notion that older animals in endemic areas have higher cumulative exposure and instead points to active, ongoing transmission cycles. The role of equid species is also critical. While horses are the primary focus of most surveillance, donkeys (Equus asinus) can serve as significant reservoirs. In the Brazilian Northeast region, 21.8% of donkeys tested positive using an rgp90 ELISA, compared to only 0.81% by AGID, conclusively demonstrating that donkeys are carriers of EIAV and can be a source of infection for other equids [11]. The lower sensitivity of AGID in donkeys raises concerns that serological surveillance relying solely on this test may underestimate the true prevalence in this species.

Geographic clustering is a dominant risk factor, consistently linked to ecological and climatic conditions. The use of spatial analysis techniques, such as Kernel density estimation, has identified high-risk clusters of EIAV in Brazil, particularly in the border areas of the states of Ceará, Pernambuco, Paraíba, and Rio Grande do Norte [13]. These clusters are often associated with regions of high equid population density and significant animal movement for sporting events and trade, which facilitates both direct and indirect contact between infected and susceptible animals [13, 41]. The humid and warmer regions of the United States, Argentina, and Brazil consistently demonstrate higher prevalence rates per province or state compared to cooler, drier areas [1]. In Mexico, risk factor analysis and cluster analysis identified that seropositive cases were geographically clustered in regions characterized by a temperate climate with summer rains [4]. These environmental conditions are directly permissive for the proliferation of the primary biological vectors.

Vector Dynamics and Transmission Ecology

The fundamental driver of EIAV transmission in the absence of iatrogenic spread is mechanical transmission by hematophagous insects, principally tabanids (deer flies, Tabanus spp. and Chrysops spp.) and stable flies (Stomoxys calcitrans). These insects act as "flying needles," transferring blood-borne virus from an infected to a susceptible host during interrupted feeding. Seminal experimental work definitively demonstrated that mechanical transmission of EIAV is successful when deer flies (Chrysops flavidus) and stable flies (Stomoxys calcitrans) feed partially on acutely infected ponies and are immediately transferred to susceptible recipient ponies to complete their blood meal [42]. The efficiency of this mechanical transmission is highly dependent on the volume of blood transferred and the viral titer of the donor horse. Acutely infected horses with high plasma viremia are far more efficient sources of infection than inapparent carriers, highlighting the importance of early detection and quarantine during febrile episodes.

The dynamics of vector populations are exquisitely sensitive to climatic conditions, which in turn dictate the seasonal and geographic patterns of EIAV transmission. Regions with substantial rainfall and high temperatures, such as the Amazon delta, support the year-round proliferation of insect vectors, creating conditions for continuous transmission pressure [36]. Yet even under these extreme conditions, the transmission rate is not uniform. A remarkable study on Marajó Island in the Amazon River delta, where approximately 40% of feral equids are seropositive, monitored 28 foals born to seropositive mares and found that only 7.14% became seropositive by the time of natural weaning [36, 38]. This low vertical and post-partum insect-mediated transmission rate, despite an immense vector population, provides critical insight: while vectors are necessary for transmission, they are not sufficient in isolation. It suggests that the risk of transmission from a seropositive mare to her foal is relatively low, and that successful transmission events may require a combination of high vector density, high donor viremia, and specific behavioral interactions between insects and hosts.

Global warming presents a paradigm-shifting threat to the global epidemiology of EIAV. Climate change is predicted to lead to increased vector movement into temperate areas that were previously free of sustained transmission, potentially triggering a surge in EIAV infections [1]. Warmer temperatures can extend the active season of tabanids and stable flies, increase their population density, and expand their geographic range into higher latitudes. This could transform regions currently classified as low-risk into endemic areas, particularly if they harbor a susceptible equid population. The recent observation of an increasing temporal trend in EIA incidence in the South region of Brazil (AAPC: 6.5; CI: 2.9 to 10.3), even as the national rate declines, may be an early warning sign of shifting vector ecology [41]. Iatrogenic transmission, through the use of contaminated needles, syringes, or blood-contaminated veterinary equipment, remains a significant and preventable risk factor. This route can amplify transmission within a population, bypassing the ecological constraints of vector biology and leading to rapid, localized outbreaks.

Emerging Concepts: Occult Infections and Diagnostic Implications

A critical dimension of EIAV epidemiology that complicates prevalence estimation and risk assessment is the phenomenon of "occult" or serologically silent infections. These are horses that harbor EIAV proviral DNA but remain persistently seronegative by conventional diagnostic methods. In a landmark study in Argentina, 18 of 33 AGID-negative, clinically normal horses were positive by a PCR targeting the gp45 gene, and all but one remained antibody-negative over a two-year observation period [32]. This finding was corroborated by positive results in OIE-recommended gag gene PCR and Western blot verification. The existence of such occult infections has profound epidemiological implications: they represent a hidden reservoir of infection that is completely invisible to standard AGID-based surveillance programs. In Mexico, hemi-nested PCR targeting the 5′-LTR/tat segment detected EIAV proviral DNA in 9 of 42 non-clinical, seronegative horses, further confirming that a substantial proportion of infected animals may be missed by serology alone [30]. These occult carriers could perpetuate transmission cycles, particularly if they experience transient, low-level viremia sufficient for vector-borne transmission. The high genetic variability of EIAV, particularly in the env and tat-gag regions, may contribute to these cryptic infections by altering epitope presentation or viral replication kinetics [16, 39]. The development of more sensitive molecular tools, such as the tat-gag-based real-time quantitative PCR (TG-qPCR) which can detect as few as 1 copy/reaction and covers Asian strains missed by standard assays, is essential for unveiling the true extent of EIAV infection [35]. The implications for global trade and movement certification are substantial, as an animal that tests negative by AGID but harbors proviral DNA represents a potential source of introduction into a naive population.

Clinical Manifestations and Pathological Features of Equine Infectious Anemia

Equine Infectious Anemia (EIA), caused by the equine infectious anemia virus (EIAV), is a globally significant lentiviral disease of Equidae that presents a remarkably heterogeneous clinical spectrum, ranging from peracute fatal disease to lifelong asymptomatic carriage [20, 37, 43]. The clinical course is profoundly influenced by a complex interplay of viral strain virulence, host genetic background, immune competence, and environmental stressors, particularly those that precipitate insect-vector activity [1, 42]. The disease is classically described as occurring in three overlapping phases, acute, chronic, and subclinical, though individual horses may experience variable transitions between these states, and the pathological underpinnings of each phase are distinct yet interconnected [28, 43].

Acute Phase: The Cytopathic Storm

The acute phase typically manifests 7–30 days post-infection and is characterized by a sudden onset of high fever, often spiking to 40–41°C, which correlates directly with the first major wave of plasma viremia [37, 43]. This febrile episode is frequently accompanied by profound thrombocytopenia, a hallmark of acute EIAV infection that distinguishes it from many other equine viral diseases. The platelet count can plummet to dangerously low levels within days, leading to a petechial and ecchymotic hemorrhagic diathesis visible on the mucosal membranes of the conjunctiva, oral cavity, and vulva [43]. Concurrently, horses develop a macrocytic, normochromic anemia, the severity of which is typically proportional to the magnitude of the viremic peak. This anemia is not merely a consequence of hemodilution; rather, it results from a combination of direct viral-induced erythrophagocytosis by activated macrophages and immune-mediated destruction of red blood cells coated with viral antigens or adsorbed immune complexes [37, 43].

Hematological examination during this phase reveals not only severe thrombocytopenia and anemia but also a transient leukopenia, particularly affecting lymphocytes and monocytes. The underlying pathomechanism involves the infection and subsequent depletion of these target cells in the bone marrow and peripheral blood [3, 24]. Clinically, affected animals appear profoundly depressed, anorexic, and may exhibit signs of weakness, ataxia, and dependent edema of the ventral abdomen, prepuce, and distal limbs [37, 43]. In peracute cases, death can occur within 2–3 weeks due to profound hypovolemic shock from internal hemorrhage or secondary bacterial infections. The pathological basis of these clinical signs is a systemic vasculitis driven by the deposition of viral antigen-antibody complexes within small vessel walls, leading to increased vascular permeability, endothelial cell damage, and microthrombosis. Gross necropsy findings in acute fatalities often include generalized lymphadenopathy, splenomegaly, hepatomegaly, and multifocal hemorrhages on serosal surfaces, myocardium, and renal cortices [24]. Histologically, the spleen and lymph nodes exhibit marked lymphoid hyperplasia with prominent germinal centers, indicative of a robust but ultimately dysregulated humoral immune response. In the liver, one observes periportal infiltration of mononuclear cells, Kupffer cell hyperplasia, and focal hepatocellular necrosis, while the kidneys display proliferative glomerulonephritis with subendothelial electron-dense deposits consistent with immune complex deposition.

Chronic Phase: Cycles of Relapse and Remission

Horses that survive the initial acute viremic episode often enter the chronic phase, which is defined by recurrent episodes of fever, anemia, and thrombocytopenia interspersed with periods of clinical remission [28, 43]. This cyclical pattern is the hallmark of chronic EIA and directly reflects the dynamic interplay between viral replication and the host’s adaptive immune response, particularly cytotoxic T lymphocytes (CTLs) and neutralizing antibodies [28, 29]. Each relapse is precipitated by the emergence of antigenic variants of EIAV, particularly in the viral envelope glycoproteins gp90 and gp45, which possess the ability to transiently escape the existing antibody and CTL responses [28, 31]. The frequency and severity of these febrile episodes tend to diminish over time as the breadth of the humoral and cellular immune responses broadens to encompass a wider array of viral epitopes, a process that may take months to years [29].

Clinically, chronic EIA horses are characterized by progressive wasting, a dull hair coat, persistent low-grade anemia (packed cell volume often between 15–25%), and intermittent dependent edema [37, 43]. The recurring episodes of viremia are associated with further thrombocytopenia and hemorrhage, though typically less severe than in the initial acute attack. The chronic anemia is a combination of ongoing hemolysis, ineffective erythropoiesis, and the myelosuppressive effects of persistent inflammation. Affected animals are often exercise-intolerant and may exhibit a profound, generalized weakness and ataxia of the hindquarters due to a combination of anemia and a myelopathy resulting from chronic immune-complex deposition in the spinal cord [37, 43]. Gross pathological findings in chronically infected horses are dominated by severe, often cachectic muscle atrophy, marked splenomegaly (referred to as "sago spleen" due to prominent lymphoid follicles on cut surface), hepatomegaly with centrilobular necrosis secondary to hypoxic injury from anemia, and generalized lymphadenopathy. Histologically, the bone marrow shows a hypercellular appearance with a left shift in erythroid precursors, reflecting a compensatory but inadequate response to the ongoing hemolysis. In the spleen and lymph nodes, there is prominent plasmacytosis and hemosiderosis, indicative of chronic immune stimulation and erythrophagocytosis. The liver frequently exhibits both periportal and centrilobular fibrosis due to repeated bouts of hypoxic injury and inflammation.

Subclinical and Asymptomatic Carrier State: The Lentiviral Equilibrium

The vast majority of EIAV-infected equids (estimated at over 90% in some endemic regions) eventually transition into a subclinical or asymptomatic carrier state, characterized by the absence of overt clinical signs despite persistent lifelong infection [9, 20, 43]. This state is maintained by a delicate balance between low-level viral replication, primarily in tissue-resident macrophages, and a potent, broadly reactive immune response dominated by high-avidity CTLs specific for conserved, nonvariable viral epitopes, particularly within the regulatory proteins Tat and Rev [28]. These animals serve as the primary reservoir for viral transmission to naïve hosts via mechanical transfer by hematophagous insects such as Tabanus spp. (horse flies) and Stomoxys calcitrans (stable flies) [1, 42]. The pathological hallmark of this latent state is the integration of the proviral DNA into the host genome of long-lived macrophages, allowing for occasional reactivation of viral replication during periods of stress, immunosuppression, or intercurrent illness [25, 43]. This reactivation can lead to transient, low-level viremia and, in some cases, a recrudescence of clinical disease, though typically less severe than the initial episode [28].

Importantly, a significant proportion of these subclinically infected horses may remain seronegative for extended periods, a phenomenon termed "occult" EIAV infection [32]. These serologically silent carriers harbor detectable proviral DNA or viral RNA in their peripheral blood or tissues but fail to mount a humoral antibody response detectable by conventional serological tests such as the agar gel immunodiffusion (AGID) test or even enzyme-linked immunosorbent assays (ELISAs) [30, 32, 39]. The discovery of these occult carriers, which can represent a substantial fraction of infected horses in some regions, has profound implications for disease control, as they pose a significant risk of transmission to naïve animals while eluding standard surveillance programs. The pathological basis of this serological silence is not fully understood but may involve low-level antigenic stimulation that fails to trigger a robust B-cell response, perhaps due to an early, dominant, and highly effective CTL response that suppresses viral replication below the threshold required for antibody generation [28, 32].

Key Pathological Mechanisms and Determinants of Outcome

The diverse clinical manifestations of EIA are underpinned by several distinct pathological processes. The hemolytic anemia and thrombocytopenia are driven by immune-mediated destruction, where viral antigens (particularly p26 and gp90) adsorbed onto platelets and erythrocytes bind circulating antibodies, leading to complement activation and splenic sequestration [43]. The fever and systemic inflammatory response are mediated by the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) from infected macrophages [24]. The lymphadenopathy and splenomegaly reflect a robust lymphoid hyperplasia in response to persistent antigenic stimulation, while the glomerulonephritis and vasculitis are classic Type III hypersensitivity reactions driven by the deposition of circulating immune complexes [24]. Notably, the pathogenicity of EIAV is directly correlated with the genetic diversity of the viral quasispecies, particularly within the env gene (encoding gp90 and gp45) and the long terminal repeat (LTR) region [16, 18]. Virulent strains exhibit a higher degree of genetic variability, allowing for rapid immune escape, whereas attenuated vaccine strains, such as the Chinese EIAVDLV121, possess a more stable genome and replicate at significantly lower levels, inducing a controlled, non-pathogenic immune response without causing histopathological lesions in target organs [24]. Furthermore, host restriction factors, including equine MX2, play a critical role in modulating viral replication in macrophages and may contribute to the establishment of the long-term asymptomatic carrier state [6, 17].

Diagnostic Strategies for EIAV: Serological Assays and Molecular Detection

The accurate and timely diagnosis of Equine Infectious Anemia Virus (EIAV) infection is the cornerstone of global control and eradication programs. As a lifelong, persistent infection for which no curative treatment exists, the identification and subsequent management (through quarantine, movement restriction, or euthanasia) of seropositive animals is mandated by the World Organisation for Animal Health (WOAH) to prevent further transmission [1, 9, 11]. The diagnostic landscape for EIAV has evolved significantly from the traditional agar gel immunodiffusion (AGID) test to a sophisticated arsenal of highly sensitive serological platforms and molecular detection methods capable of identifying viral nucleic acids. The selection and interpretation of these assays are complicated by the virus's substantial genetic diversity, the phenomenon of serologically silent or "occult" infections, and the need for assays that balance high throughput with absolute specificity for trade and regulatory purposes [30, 32, 41]. This section provides an exhaustive, mechanistic, and comparative analysis of the serological and molecular strategies employed for EIAV detection, dissecting their biological principles, diagnostic performance, inherent limitations, and strategic roles within comprehensive surveillance frameworks.

Serological Assays: The Established Foundation and Its Modern Refinements

For decades, serological detection of antibodies against EIAV has been the primary diagnostic modality. The rationale is rooted in the host's robust and persistent humoral immune response to the virus, which, unlike the transient viremia, remains detectable for the life of the animal. The WOAH-prescribed and traditional gold standard test is the Agar Gel Immunodiffusion (AGID) test, also known as the Coggins test [4, 5, 10]. This assay detects precipitating antibodies, predominantly of the IgG class, directed against the major core protein p26. The p26 antigen, a highly conserved structural component of the viral capsid, is utilized in a simple radial diffusion format where antigen and antibody form visible lines of precipitation within an agarose gel [39, 45].

While the AGID test is celebrated for its remarkable specificity and low cost, its analytical sensitivity is a critical weakness. This has been demonstrated consistently across numerous comparative studies. For instance, AGID is reported to be 8 to 16 times less sensitive than commercial enzyme-linked immunosorbent assays (ELISAs) and a staggering 128 to 256 times less sensitive than Western blotting [43]. Furthermore, in a study involving natural infections in Brazil, a tat-gag PCR detected proviral DNA in 7% of animals that were negative by AGID, and 26% of AGID-negative animals were positive by at least one ELISA, underscoring the test's inability to identify low-level or early-stage infections [39]. A comparative evaluation of four commercial AGID kits (Idexx, VMRD, IDvet, and NECVB) using sera from experimentally infected and field horses found that all kits had virtually identical performance, with 100% sensitivity and specificity when compared to one another, but this high concordance does not address the fundamental sensitivity deficit of the AGID format itself [7].

The transition to Enzyme-Linked Immunosorbent Assays (ELISAs) has been the most impactful diagnostic advancement. ELISAs offer significantly higher analytical sensitivity, quantitative or semi-quantitative readouts, and the capacity for high-throughput automation, making them ideal for large-scale surveillance programs [44, 47]. Two principal formats have been developed and validated: indirect ELISAs, which use immobilized antigen to capture serum antibodies, and competitive ELISAs (cELISA), which rely on a labeled monoclonal antibody competing with serum antibodies for a specific viral epitope.

The antigenic targets for ELISAs have expanded significantly beyond the p26 core protein. While p26-based assays are effective, the use of envelope glycoproteins, specifically the surface unit gp90 and the transmembrane unit gp45, offers distinct advantages. Gp90 is the primary target for neutralizing antibodies and contains immunodominant regions, while gp45 is crucial for viral entry and fusion. An indirect ELISA using synthetic peptides derived from a conserved region of gp90 demonstrated a sensitivity of 85.3% and specificity of 97.9% when compared to AGID, identifying 29.4% more seropositive samples [4]. Similarly, a double-antigen sandwich colloidal gold immunochromatographic (GICG) test strip incorporating both p26 and gp45 as capture antigens showed a sensitivity 8 to 16 times higher than commercial ELISAs and 128 to 256 times higher than AGID, with a 100% coincidence rate with a reference cELISA (NECVB-cELISA) in vaccine-immunized horses [43]. An in-house indirect ELISA using synthetic peptides from both gp90 and gp45 (ELISAgp90/45) demonstrated an analytical sensitivity 800 times greater than AGID for strong positive sera and 400 times greater for weak positive sera, with a diagnostic sensitivity of 99.59% and specificity of 90.32% compared to AGID as the gold standard [10]. These data collectively confirm that ELISAs, particularly those targeting envelope glycoproteins, are superior screening tools capable of detecting lower antibody titers that are missed by the AGID test.

However, the serological approach is not without profound challenges. The most significant is the existence of serologically silent or "occult" EIAV infections. This phenomenon was definitively documented in a landmark study in Argentina, where 18 out of 33 seronegative horses (54.5%) were found to harbor EIAV proviral DNA by PCR targeting the gp45 gene [32]. Critically, these horses remained seronegative by AGID, ELISA, and even Western blot for at least two years, despite having detectable lymphocyte proliferative responses to viral peptides. These horses appeared clinically normal with no gross immunodeficiency, indicating that the serological silence is not due to anergy but rather a state of very low or restricted viral replication that fails to trigger a sustained, detectable antibody response [32]. This finding has profound implications for control programs that rely solely on antibody detection, as these occult carriers represent a cryptic reservoir of infection that can potentially transmit the virus, particularly via mechanical insect vectors. The presence of such animals, combined with the potential for prolonged seroconversion windows (up to 28 days or more after infection), makes the exclusive reliance on serology a risky strategy for declaring a horse free of EIAV [30].

Molecular Detection: Direct Pathogen Identification and the Challenge of Genetic Diversity

To overcome the inherent limitations of serology, molecular diagnostic methods that directly detect the virus's genetic material (RNA or proviral DNA) have become indispensable, particularly for confirming suspicious cases, diagnosing early infections, and identifying occult carriers. Polymerase Chain Reaction (PCR) and its variants, including nested PCR, hemi-nested PCR, and real-time quantitative PCR (qPCR), represent the most widely adopted molecular platforms.

The primary challenge for molecular detection is the remarkable genetic diversity of EIAV. The virus is a lentivirus with an error-prone reverse transcriptase, leading to a high mutation rate and the existence of distinct global lineages or clades. Phylogenetic analyses have demonstrated substantial heterogeneity, even within geographically restricted regions. For example, complete genome sequencing of Brazilian EIAV strains from the Pantanal region revealed only 88.6% nucleotide identity with each other and 75.8% to 77.3% identity with North American, Asian, and European reference strains, forming a separate monophyletic group [14]. Similarly, a study of four North American isolates (from PA, TN, NC, and FL) found nucleotide sequence identity between them as low as 80.1%, with some values being comparable to the divergence between these North American strains and Asian isolates like EIAVLIA (78.0%) [16]. A global phylogeographic analysis even suggested that Hungary was the most likely ancestral origin for many circulating lineages, emphasizing the deep evolutionary history and global dispersal of diverse viral strains [15].

This genomic variability poses a direct threat to the reliability of PCR assays. Most early PCR methods, including the standard qPCR recommended by WOAH and many conventional PCRs, were designed based on conserved regions of the gag gene. However, it is now clear that the gag gene, while being the most conserved structural gene, still exhibits significant sequence heterogeneity that can lead to primer-template mismatches and false-negative results, particularly with Asian and South American strains [22, 35, 37]. For instance, a gag-based PCR was able to detect EIAV in only 3 of 11 seropositive horses from Mongolia, likely due to sequence diversity in the primer binding sites [23]. In Iraq, a molecular study targeting the gag gene successfully amplified a 271 bp fragment from 16.66% of sampled horses, but the phylogenetic analysis placed these isolates in distinct clades, demonstrating the genetic divergence even at a local level [37].

In response to this challenge, the field has moved towards targeting more conserved genomic regions or multi-target assays. The most innovative approach has been the development of a tat-gag-based real-time quantitative PCR (TG-qPCR). This assay targets the intergenic region between the tat and gag genes, a region that has been demonstrated to be relatively well-conserved across all known EIAV strains, including those from Asia, Europe, and the Americas. This TG-qPCR showed remarkable inclusivity, with a detection limit down to 1 copy/reaction for both viral RNA and proviral DNA, and it was able to detect Asian strains (including Chinese EIAV strains) that were missed by the standard WOAH-recommended gag-based qPCR [35]. Similarly, a hemi-nested PCR targeting the 5′-LTR/tat segment was effective in identifying proviral DNA in seronegative, clinically normal horses in Mexico, detecting 9 of 42 non-clinical horses that were AGID-negative, with BLAST analysis showing 83–93% identity to known EIAV isolates [30]. The long terminal repeat (LTR) and tat regions are thus emerging as critical molecular targets due to their relative conservation in functional domains despite overall variability in other parts of the genome [8, 18, 30].

Beyond PCR, alternative molecular amplification strategies are being explored to provide simpler, more field-deployable diagnostics. A Reverse Transcriptase Loop-Mediated Isothermal Amplification (RT-LAMP) assay has been developed, targeting a conserved sequence of the gag gene. This method operates at a constant temperature (63°C) and produces results in roughly 2 hours, with a sensitivity of approximately 100 copies/μL. The assay demonstrated high specificity, showing no amplification from other equine bacterial pathogens, making it a potential candidate for point-of-care testing or use in resource-limited laboratories where expensive thermocyclers are unavailable [46].

The primary limitation of molecular detection is its inability to distinguish between an active, transmissible infection and residual, non-infectious nucleic acid from, for example, a recently cleared infection. Furthermore, the presence of proviral DNA in latently infected cells can be detected even when the animal is not viremic. Therefore, a positive PCR result must be interpreted in the context of clinical signs and serological status. However, for the critical task of identifying an animal that has ever been infected, which is the regulatory requirement for international movement, molecular detection is the definitive confirmatory tool for ambiguous serological results and for revealing the true prevalence of EIAV in a population.

Prevention, Control, and Biosecurity Measures for Equine Infectious Anemia Virus

The prevention and control of Equine Infectious Anemia (EIA) represents a formidable global challenge, rooted in the unique biological properties of the etiologic agent, Equine Infectious Anemia Virus (EIAV), a macrophage-tropic lentivirus of the Retroviridae family. The fundamental obstacle to eradication lies in the virus's capacity to integrate a DNA provirus into the host genome, establishing a lifelong, persistent infection in all equid species [11, 43]. Infected animals, whether they exhibit acute clinical episodes or remain subclinical carriers, constitute a permanent reservoir of infectious virus, capable of transmitting the agent to susceptible cohorts via mechanical vectors or iatrogenic means [9]. Consequently, control strategies are predicated not on therapeutic intervention, as no curative antiviral therapy is approved for field use, but on rigorous surveillance, strict biosecurity protocols, and the management of vector populations. The World Organisation for Animal Health (WOAH) prescribes a framework that emphasizes the identification and elimination of the viral reservoir, a strategy that must be adapted to the diverse epidemiological landscapes encountered globally.

Regulatory Frameworks and the Test-and-Slaughter Paradigm

The cornerstone of EIA control in most non-endemic nations is a legislated test-and-slaughter or test-and-segregation policy. This approach relies on mandatory serological testing for movement, sale, or exhibition, with the objective of identifying and removing seropositive animals from the population before they can serve as a source of infection. The WOAH prescribes the agar gel immunodiffusion (AGID) test, known as the Coggins test, as the gold standard for international trade and official regulatory action [4, 10]. While the AGID test is specific and inexpensive, its limited analytical sensitivity is a critical weakness; it can fail to detect early-stage infections or animals with declining antibody titers, potentially allowing serologically silent carriers to evade detection [4, 10]. Research from Mexico and Argentina has demonstrated that the AGID test identifies significantly fewer infected animals compared to more sensitive enzyme-linked immunosorbent assays (ELISAs), with one study revealing that a synthetic gp90-based ELISA detected 29.4% more seropositive samples than the concurrent AGID test [4, 5]. This diagnostic gap has profound implications for control programs, as the undetected positive animal remains in the herd, perpetuating transmission cycles.

The feasibility of a test-and-slaughter policy is highly dependent on the prevalence of infection and the economic context. In the United States, where sporadic cases and low prevalence have been maintained for decades, euthanasia of seropositive horses is a routine and effective measure [1]. Conversely, in regions with an exceptionally high prevalence, such as the Pantanal region of Brazil or the Amazon delta on Marajó Island, the mass euthanasia of infected animals is not ecologically or economically viable. In these endemic zones, where approximately 40% of equids may be seropositive, alternative management strategies must be pursued, focusing on stringent vector control and the segregation of positive from negative cohorts [14, 36, 38]. The geographic clustering of high-risk areas, as identified in Brazil's Northeast and Central-West regions, underscores the need for spatially targeted interventions rather than blanket national policies [13, 41]. Furthermore, the presence of EIAV in donkeys, which often serve as neglected reservoirs, complicates control efforts. In northeastern Brazil, donkeys have been shown to harbor proviral DNA despite seronegativity on AGID, indicating that they can act as cryptic sources of infection and must be included in surveillance programs [11].

Diagnostic Strategies for Enhanced Surveillance

Effective prevention hinges on the deployment of diagnostic tools that can detect infection at the earliest possible time point, especially given the phenomenon of "occult" or serologically silent infections. Standard serological methods like AGID rely on the detection of antibodies against the p26 capsid protein, but infected horses may remain seronegative for extended periods, sometimes over 24 months, while still harboring viral nucleic acid, as documented in a cohort from Argentina [32]. Furthermore, naturally infected horses in Mexico have been found positive by nested PCR targeting the LTR/tat region even when their sera were non-reactive on AGID, emphasizing that sole reliance on serology creates a dangerous gap in surveillance [30]. Therefore, a dual-tiered diagnostic approach is essential for robust control: high-sensitivity screening tests followed by confirmation with specific assays.

Several advanced diagnostic platforms have been developed to address these deficiencies. Novel colloidal gold immunochromatographic (GICG) test strips have demonstrated remarkable sensitivity, detecting EIAV antibodies at concentrations 128 to 256 times lower than the AGID test, making them suitable for rapid, point-of-care screening in field settings [43]. Similarly, a colloidal gold immunochromatographic strip utilizing a p26-gp90 fusion protein has shown superior stability and specificity, enabling on-site detection within minutes [2]. For molecular detection, a real-time quantitative PCR targeting the conserved tat-gag junction (TG-qPCR) has been developed to overcome the high genetic diversity of EIAV strains, particularly those circulating in Asia, which are often missed by conventional gag-based qPCR protocols [35]. This assay, with a limit of detection of 1 copy per reaction, can identify proviral DNA in peripheral blood mononuclear cells before seroconversion occurs, providing a critical window for early intervention [35]. The Loop-mediated Isothermal Amplification (LAMP) assay also offers a rapid, simple, and sensitive alternative for molecular detection in resource-limited settings, without the need for sophisticated thermal cycling equipment [46]. Integrating these molecular tools into national surveillance programs is vital for identifying the true prevalence of infection and closing the diagnostic window of vulnerability.

Vector Biology, Environmental Management, and Transmission Risk

A comprehensive biosecurity plan must account for the primary natural route of EIAV transmission: mechanical transfer by hematophagous arthropod vectors. Unlike biological transmission, where the pathogen replicates within the vector, EIAV is transmitted mechanically when blood-feeding insects, particularly deer flies (Chrysops spp.) and stable flies (Stomoxys calcitrans), interrupt a blood meal on an acutely infected, viremic animal and immediately transfer contaminated mouthparts to a susceptible host [42]. The risk of vector-borne transmission is directly proportional to the ambient temperature and humidity, which govern vector population density and feeding activity. Global epidemiological data reveal that EIAV prevalence is significantly higher in humid, tropical, and subtropical regions, such as the southern United States, Mexico, Central America, and the Brazilian Pantanal, where insect activity is nearly year-round [1, 13]. The spatial analysis of outbreaks in Brazil's Northeast region has identified clusters of cases along state borders, likely reflecting areas of intense animal movement combined with high vector pressure [13]. Climate change poses a particular threat to temperate zones; as global temperatures rise, the distribution of competent vectors is expected to expand poleward, potentially introducing EIAV into previously disease-free regions [1].

To mitigate vector-borne transmission, biosecurity measures must focus on reducing vector-host contact. This includes the strategic scheduling of high-risk equine events (e.g., fairs, races, breeding sales) during seasons of low vector activity. Stabling horses during peak feeding hours of dawn and dusk, and installing physical barriers such as insect-proof screens and fans in barns, can reduce exposure. The use of insecticide sprays, pour-ons, and repellents, particularly those containing pyrethroids, should be applied regularly to the coat of animals. Environmental management is equally critical: the elimination of breeding sites for stable flies, such as decaying organic matter, wet hay, and manure piles, is a fundamental component of integrated pest management. Importantly, insect transmission is highly inefficient unless an animal is in the acute, febrile stage of disease with a high-titer viremia. Most natural transmissions occur when a susceptible animal is housed in close proximity to a clinically ill horse during a febrile episode. This underscores the importance of rapid isolation of any horse showing pyrexia or clinical signs consistent with EIA, pending confirmatory test results.

Iatrogenic Transmission and Vertical Transmission

Beyond vector-borne spread, iatrogenic transmission via contaminated fomites represents a completely preventable but historically significant route of dissemination. The reuse of needles, syringes, and intravenous administration sets, common in mass vaccination campaigns, blood transfusions, and treatment of equine colic, can efficiently transfer infected blood cells from a carrier horse to a susceptible one. Strict adherence to single-use needle policies and rigorous sterilization of surgical and dental instruments is mandatory. Blood products, including plasma and whole blood transfusions, must only be sourced from donors that have tested negative for EIAV within the previous 30-60 days. Additionally, any equipment that may be contaminated with blood, including dental floats, hoof knives, and twitches, should be cleaned and disinfected between patients.

Vertical transmission from mare to foal, while documented, appears to occur at a relatively low frequency even in highly endemic regions. A critical longitudinal study on Marajó Island, where 40% of feral mares were seropositive, monitored 28 foals from birth to natural weaning and found that only 7.14% (2/28) became seropositive, despite constant exposure to insect vectors and the proximity of their infected dams [36, 38]. This suggests that the risk of in-utero or colostral transmission is low, and that seropositive mares in valuable breeding programs may be bred and managed to produce seronegative offspring, provided the foals are strictly protected from insect bites post-partum [36, 38]. Nevertheless, all foals born to seropositive mares should be tested after weaning to confirm their seronegative status before being introduced to the general population.

Special Considerations for Endemic and High-Prevalence Regions

In high-prevalence settings where euthanasia is not a viable option, the control paradigm shifts from eradication to risk mitigation. This involves the creation of separate, physically distinct management units for seropositive and seronegative animals, with dedicated equipment and caretakers to prevent cross-contamination. In areas such as the Pantanal and the Brazilian Northeast, where spatial and spatiotemporal clusters of high transmission risk have been identified, targeted surveillance and intensified vector control in those specific municipalities can yield disproportionate benefits [13, 41]. The use of topical insect repellents and insecticide-treated blankets or fly masks becomes a year-round necessity. Vaccination, if a safe and effective vaccine were widely available, would be a game-changer in these regions. Currently, the only widely used EIAV vaccine is the Chinese attenuated live vaccine (EIAV-DLV121), which was developed in the 1970s through serial passage and has been instrumental in controlling the disease in China [20, 24]. This vaccine induces strong resistance against subsequent infection with virulent strains, mediated in part by upregulation of Toll-like receptor 3 (TLR3) and interferon-β pathways [34]. However, its use outside of China is restricted due to concerns regarding reversion to virulence, the potential for spread of the vaccine strain in naive populations, and the inability to differentiate vaccinated from naturally infected animals using current serological tests [33]. The development of a modern, safe, and DIVA-compatible (Differentiating Infected from Vaccinated Animals) subunit or vectored vaccine remains a high research priority, with mathematical modeling suggesting that repeated antibody infusions could theoretically clear infection under ideal conditions [29, 31]. Until such a vaccine is licensed, rigorous testing, quarantine, and vector management will remain the only effective tools for the global prevention and control of this insidious lentivirus.

References

[1] Thieulent CJ, Carossino M, Reis J, Vissani MA, Barrandeguy ME, Valle-Casuso J, et al.. Equine infectious anemia virus worldwide prevalence: A 24-year retrospective review of a global equine health concern with far-reaching implications.. Veterinary Microbiology. 2025. DOI: https://doi.org/10.1016/j.vetmic.2025.110548

[2] Wang J, Qiu J, Wang M, Wu X, Li X, Zhang H. Development of a colloidal gold immunochromatographic strip to detect equine infectious anemia virus. Virology Journal. 2025. DOI: https://doi.org/10.1186/s12985-025-02815-6

[3] Schimmich C, Vabret A, Zientara S, Valle-Casuso J. Equine Infectious Anemia Virus Cellular Partners Along the Viral Cycle. Viruses. 2024. DOI: https://doi.org/10.3390/v17010005

[4] Acevedo-Jiménez GE, Morales-González C, Akbarin MM, Rodríguez-Murillo C, González-Fernández VD, Vega LdMÁl, et al.. "Synthetic gp90 peptide ELISA for equine infectious anemia virus: Improved sensitivity and risk factor insights".. Preventive Veterinary Medicine. 2026. DOI: https://doi.org/10.1016/j.prevetmed.2026.106811

[5] Villa-Mancera A, Villegas-Bello L, Campos-García H, Ortega-Vargas S, Cruz-Aviña J, Patricio-Martínez F, et al.. Prevalence of equine infectious anemia virus in horses and donkeys determined by comparison of ELISA and AGID in Mexico. Arquivo Brasileiro de Medicina Veterinária e Zootecnia. 2024. DOI: https://doi.org/10.1590/1678-4162-13142

[6] Wang X, Zhang X, Ma W, Li J, Wang X. Host cell restriction factors of equine infectious anemia virus. Virologica Sinica. 2023. DOI: https://doi.org/10.1016/j.virs.2023.07.001

[7] Bannai H, Kambayashi Y, Nemoto M, Yamanaka T, Tsujimura K. Comparison of 4 agar gel immunodiffusion kits for serologic detection of equine infectious anemia virus antibodies. Journal of Veterinary Diagnostic Investigation. 2023. DOI: https://doi.org/10.1177/10406387231171567

[8] Li J, Zhang X, Bai B, Zhang M, Ma W, Lin Y, et al.. Identification of a Novel Post-transcriptional Transactivator from the Equine Infectious Anemia Virus. Journal of Virology. 2022. DOI: https://doi.org/10.1128/jvi.01210-22

[9] Lupulović D, Savić S, Gaudaire D, Berthet N, Grgić Ž, Matović K, et al.. Identification and genetic characterization of equine infectious anemia virus in Western Balkans. BMC Veterinary Research. 2021. DOI: https://doi.org/10.1186/s12917-021-02849-2

[10] Rusi RC, García L, Cámara M, Soutullo A. Validation of an indirect in-house ELISA using synthetic peptides to detect antibodies anti-gp90 and gp45 of the Equine Infectious Anemia Virus (EIAV).. Equine Veterinary Journal. 2022. DOI: https://doi.org/10.1111/evj.13555

[11] Costa VMD, Cursino AE, Luiz APM, Braz GF, Cavalcante PH, Souza CEA, et al.. Equine Infectious Anemia Virus (EIAV): Evidence of Circulation in Donkeys from the Brazilian Northeast Region.. Journal of Equine Veterinary Science. 2021. DOI: https://doi.org/10.1016/j.jevs.2021.103795

[12] Wang X, Wang Y, Bai B, Zhang M, Chen J, Zhang X, et al.. Truncation of the Cytoplasmic Tail of Equine Infectious Anemia Virus Increases Virion Production by Improving Env Cleavage and Plasma Membrane Localization. Journal of Virology. 2021. DOI: https://doi.org/10.1128/JVI.01087-21

[13] Bezerra CDS, Anjos DM, Falcão BM, Bezerra CW, Moraes DJA, Nogueira DB, et al.. True Prevalence and Spatial Distribution of Equine Infectious Anemia Virus (EIAV) in Horses from Northeast Region of Brazil. Acta Scientiae Veterinariae. 2021. DOI: https://doi.org/10.22456/1679-9216.116488

[14] Malossi C, Fioratti E, Cardoso J, Magro AJ, Kroon E, Aguiar DM, et al.. High Genomic Variability in Equine Infectious Anemia Virus Obtained from Naturally Infected Horses in Pantanal, Brazil: An Endemic Region Case. Viruses. 2020. DOI: https://doi.org/10.3390/v12020207

[15] Jara M, Frias-De-Diego A, Machado G. Phylogeography of equine infectious anemia virus. bioRxiv. 2019. DOI: https://doi.org/10.3389/fevo.2020.00127

[16] Cook S, Li G, Zheng Y, Willand ZA, Issel C, Cook R. Molecular Characterization of the Major Open Reading Frames (ORFs) and Enhancer Elements From Four Geographically Distinct North American Equine Infectious Anemia Virus (EIAV) Isolates.. Journal of Equine Veterinary Science. 2020. DOI: https://doi.org/10.1016/j.jevs.2019.102852

[17] Meier K, Vasudevan AAJ, Zhang Z, Bähr A, Kochs G, Häussinger D, et al.. Equine MX2 is a restriction factor of equine infectious anemia virus (EIAV).. Virology. 2018. DOI: https://doi.org/10.1016/j.virol.2018.07.024

[18] Wang X, Liu Q, Wang Y, Wang S, Chen J, Lin Y, et al.. Characterization of Equine Infectious Anemia Virus Long Terminal Repeat Quasispecies In Vitro and In Vivo. Journal of Virology. 2018. DOI: https://doi.org/10.1128/JVI.02150-17

[19] Wang J, Wang Q, Hao S, Guo C, An J, Zhang Q, et al.. Thermostable properties of the equine infectious anemia virus nucleocapsid protein NCp11.. Biochemical and Biophysical Research Communications - BBRC. 2019. DOI: https://doi.org/10.1016/j.bbrc.2019.01.137

[20] Wang H, Rao D, Fu X, Hu M, Dong J. Equine infectious anemia virus in China. OncoTarget. 2017. DOI: https://doi.org/10.18632/oncotarget.20381

[21] Domínguez-Odio A, González LIC, Alfonso DM, Guevara-Hernández F, Arias MALO, Zayas MP, et al.. Serodiagnosis of equine infectious anemia by indirect ELISA based on a novel synthetic peptide derived from gp45 glycoprotein. Veterinary research communications. 2025. DOI: https://doi.org/10.1007/s11259-025-10707-x

[22] Tang Q, Zhang H, Han J, Li L, Liu T, Xu J, et al.. Preliminary Study on a RT-PCR Method for the Equine Infectious Anemia Virus Detection. . 2017. DOI: https://doi.org/10.2991/bbe-17.2017.51

[23] Sharav T, Konnai S, Ochirkhuu N, Ts E, Mekata H, Sakoda Y, et al.. Detection and molecular characterization of equine infectious anemia virus in Mongolian horses. Journal of Veterinary Medical Science. 2017. DOI: https://doi.org/10.1292/jvms.17-0202

[24] Liu Q, Ma J, Wang X, Xiao F, Li L, Zhang J, et al.. Infection with equine infectious anemia virus vaccine strain EIAVDLV121 causes no visible histopathological lesions in target organs in association with restricted viral replication and unique cytokine response. Veterinary Immunology and Immunopathology. 2016. DOI: https://doi.org/10.1016/j.vetimm.2016.01.006

[25] Liu Q, Wang X, Ma J, He X, Wang X, Zhou J. Characterization of Equine Infectious Anemia Virus Integration in the Horse Genome. Viruses. 2015. DOI: https://doi.org/10.3390/v7062769

[26] Du C, Ma J, Liu Q, Li Y, He X, Lin Y, et al.. Mice transgenic for equine cyclin T1 and ELR1 are susceptible to equine infectious anemia virus infection. Retrovirology. 2015. DOI: https://doi.org/10.1186/s12977-015-0163-7

[27] Chen C, Vincent O, Jin J, Weisz O, Montelaro R. Functions of Early (AP-2) and Late (AIP1/ALIX) Endocytic Proteins in Equine Infectious Anemia Virus Budding*. Journal of Biological Chemistry. 2005. DOI: https://doi.org/10.1074/jbc.M509317200

[28] Mealey R, Zhang B, Leib SR, Littke MH, McGuire T. Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus.. Virology. 2003. DOI: https://doi.org/10.1016/S0042-6822(03)00344-1

[29] Hull-Nye D, Meadows T, Smith? SR, Schwartz EJ. Key Factors and Parameter Ranges for Immune Control of Equine Infectious Anemia Virus Infection. Viruses. 2023. DOI: https://doi.org/10.3390/v15030691

[30] Romo-Sáenz C, Tamez-guerra P, Olivas-Holguin A, Ramos-Zayas Y, Obregón-Macías N, González-Ochoa G, et al.. Molecular detection of equine infectious anemia virus in clinically normal, seronegative horses in an endemic area of Mexico. Journal of Veterinary Diagnostic Investigation. 2021. DOI: https://doi.org/10.1177/10406387211006195

[31] Schwartz EJ, Costris-Vas C, Smith? SR. Modelling Mutation in Equine Infectious Anemia Virus Infection Suggests a Path to Viral Clearance with Repeated Vaccination. Viruses. 2021. DOI: https://doi.org/10.3390/v13122450

[32] Ricotti S, García MI, Veaute C, Bailat A, Lucca E, Cook R, et al.. Serologically silent, occult equine infectious anemia virus (EIAV) infections in horses.. Veterinary Microbiology. 2016. DOI: https://doi.org/10.1016/j.vetmic.2016.03.007

[33] Maeda K. Vaccine of Equine infectious Anemia. Theoretical and Natural Science. 2024. DOI: https://doi.org/10.54254/2753-8818/61/20241443

[34] Ma J, Wang S, Lin Y, Liu H, Liu Q, Wei H, et al.. Infection of equine monocyte-derived macrophages with an attenuated equine infectious anemia virus (EIAV) strain induces a strong resistance to the infection by a virulent EIAV strain. Veterinary Research. 2014. DOI: https://doi.org/10.1186/s13567-014-0082-y

[35] Li S, Guo K, Wang X, Lin Y, Wang J, Wang Y, et al.. Development and evaluation of a real-time quantitative PCR for the detection of equine infectious anemia virus. Microbiology spectrum. 2023. DOI: https://doi.org/10.1128/spectrum.02599-23

[36] Resende CF, Santos AM, Cook R, Victor RM, Câmara RJF, Gonçalves GP, et al.. Low transmission rates of Equine infectious anemia virus (EIAV) in foals born to seropositive feral mares inhabiting the Amazon delta region despite climatic conditions supporting high insect vector populations. BMC Veterinary Research. 2022. DOI: https://doi.org/10.1186/s12917-022-03384-4

[37] Mosa AH, Badawi NM, Hussein ZS, Mohammed AJ. Molecular detection of equine infectious anemia viruses using conventional PCR and primer design for virus gag-gene region in the middle Iraqi provinces. Sumer 3. 2023. DOI: https://doi.org/10.21931/rb/css/2023.08.03.62

[38] Cf R, Am S, Rf C, Rm V, Rjf C, Gp G, et al.. Low Transmission Rates of Equine Infectious Anemia Virus (EIAV) in Foals Born To Seropositive Feral Mares Inhabiting the Amazon Delta Region Despite Climatic Conditions Supporting High Insect Vector Populations. . 2021. DOI: https://doi.org/10.21203/RS.3.RS-589091/V1

[39] Cursino AE, Lima M, Nogueira MF, Aguiar DMd, Luiz APMF, Alves P, et al.. Identification of large genetic variations in the equine infectious anemia virus tat-gag genomic region.. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13946

[40] Alnaeem A, Hemida M. Surveillance of the equine infectious anemia virus in Eastern and Central Saudi Arabia during 2014-2016. Veterinary World. 2019. DOI: https://doi.org/10.14202/vetworld.2019.719-723

[41] Silva VVd, Leite DPdSBM, Reis JdCSC, Braz BMdA, Junior JWP, Almeida JCd, et al.. Clusters of high transmission risk and time series for Equine Infectious Anemia in Brazil.. Research in Veterinary Science. 2025. DOI: https://doi.org/10.1016/j.rvsc.2025.105628

[42] Foil L, Cl M, Wv A, Issel C. Mechanical transmission of equine infectious anemia virus by deer flies (Chrysops flavidus) and stable flies (Stomoxys calcitrans).. American Journal of Veterinary Research. 1983. DOI: https://doi.org/10.2460/ajvr.1983.44.01.155

[43] Zhang Z, Guo K, Chu X, Liu M, Du C, Hu Z, et al.. Development and evaluation of a test strip for the rapid detection of antibody against equine infectious anemia virus. Applied Microbiology and Biotechnology. 2024. DOI: https://doi.org/10.1007/s00253-023-12980-9

[44] Domínguez MCR, Montes-de-Oca-Jiménez R, Chagoyán JCV, Pliego A, Guerrero JAV, González LIC, et al.. Evaluation of Equine Infectious Anemia Virus by the Indirect Enzyme-linked Immunosorbent Assay EIA-LAB as Screening Tools in Mexico.. Journal of Equine Veterinary Science. 2021. DOI: https://doi.org/10.1016/j.jevs.2021.103372

[45] Hussain K. Antigenic Analysis of Equine Infectious Anemia Virus Using Monoclonal Antibodies.. . 2018. DOI: https://doi.org/10.31390/gradschool_disstheses.4508

[46] Han J, Zhang H, Tang Q, Liu T, Xu J, Li L, et al.. Preliminary Study of LAMP Method for the Detection of Equine Infectious Anemia Virus. . 2017. DOI: https://doi.org/10.2991/BBE-17.2017.79

[47] Álvarez I, Cipolini F, Wigdorovitz A, Trono K, Barrandeguy M. The efficacy of ELISA commercial kits for the screening of equine infectious anemia virus infection.. Revista Argentina de Microbiología. 2015. DOI: https://doi.org/10.1016/j.ram.2014.12.001